Patient Resources
About our Sponsor
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes.
Visit Castle Biosciences at the Following Events
- DERM2023 NP+PA Conference, August 3 – 6
- AAD Innovation, August 10 - 13
- Fall Maui Derm NP+PA, September 27 – 30
Attending any of these events? Let us know!
Our Products
Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma
Highlights
- The first melanoma prognostic test, strongly evidenced with over 35 peer-reviewed publications and more than 9,000 patients studied
- The most comprehensive result, integrating tumor biology and clinicopathologic features to answer likelihood of a positive sentinel lymph node and risk of recurrence for patients with melanoma
- The only melanoma prognostic test shown to be associated with improved patient survival
Aids in the diagnosis and management decisions for patients with ambiguous melanocytic lesions
Highlights
- Provides increased confidence and clarity for dermatopathologists and dermatologists in both diagnosis and patient management decisions
- Included in three national guidelines as an ancillary test option for facilitating a more definitive diagnosis
- Peer-reviewed publications support clinical validity and utility
Identifies the risk of metastasis in patients with squamous cell carcinoma (SCC) and one or more risk factors
Highlights
- Delivers prognostic precision as a significant predictor of metastasis and the strongest predictor of risk, compared to traditional clinical and pathological factors
- Provides unique, complementary information for SCC management to better inform choices about treatment and follow-up care
- Supported by 12 peer-reviewed publications with proven clinical validity and utility
Provides comprehensive profiling for evaluating metastatic risk in uveal melanoma
Highlights
- The standard of care for prognosis of newly diagnosed uveal melanoma in the National Comprehensive Cancer Network (NCCN) Guidelines
- Used by 90% of U.S. ocular oncology institutions to help physicians optimize patient management based on metastatic risk
- Supported by more than 20 peer-reviewed publications with proven clinical validity and utility
Featured Videos
How Castle Biosciences is Changing the Management of Dermatologic Cancers
Overview of Castle Biosciences' Diagnostic Offering for Dermatologic Cancers
Morgan’s Story – How the DecisionDx-Melanoma report provided her confidence
